Figma Shares Indicated To Open $105/$110
Robert L. Scavo, Chief Information Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), a healthcare company with a market capitalization of $3.5 billion, has sold shares of the company’s stock valued at approximately $51,236. The transaction, reported on March 27, involved the sale of 2,864 shares at a weighted-average price of $17.89 per share. These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this transaction, Scavo holds 702,953 shares of Alignment Healthcare. The shares were sold in multiple transactions with prices ranging from $17.50 to $18.05. According to InvestingPro data, ALHC stock has delivered an impressive 269% return over the past year and is currently trading near its 52-week high of $18.44. With 11 additional exclusive ProTips and comprehensive analysis available, investors can access deeper insights into ALHC’s valuation and growth prospects through InvestingPro’s detailed research reports.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. Additionally, Alignment Healthcare achieved its first year of adjusted EBITDA profitability, marking a significant milestone. The company saw a 59% membership growth in 2024, with notable expansion outside California, particularly in Nevada. Looking ahead, Alignment Healthcare provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion, and adjusted gross profit ranging from $415 million to $445 million.
In further developments, Piper Sandler raised its price target for Alignment Healthcare to $21, maintaining an Overweight rating, citing confidence in the company’s growth strategies. Piper Sandler highlighted the company’s "flywheel" approach, emphasizing its effectiveness in expanding beneficiary choice and optimizing clinical outcomes. Meanwhile, Raymond (NSE:RYMD) James increased its price target for Alignment Healthcare to $19, reiterating a Strong Buy rating following the company’s robust fourth-quarter performance. The firm noted that Alignment Healthcare exceeded expectations in membership growth and top-line performance, with a lower-than-expected medical loss ratio contributing to an adjusted EBITDA beat. Raymond James emphasized the company’s potential for sustained growth and improved profitability by leveraging its clinical model and operational scale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.